Abstract

Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 trials to assess the PFS benefit of ixazomib plus lenalidomide-dexamethasone (Rd) vs placebo-Rd (TOURMALINE-MM1/-MM2) or ixazomib vs placebo (TOURMALINE-MM3/-MM4) in specific high-risk CAs. After a pooled median follow-up of 25.6 months, the hazard ratio (HR) for PFS with ixazomib- vs placebo-based therapy for high-risk patients was 0.74 (95% confidence interval [CI]: 0.59–0.93; median PFS [mPFS] 17.8 vs 13.2 months), and 0.70 (95% CI: 0.62–0.80; mPFS 26.3 vs 17.6 months) for complementary standard-risk patients. The HR for expanded high-risk patients was 0.75 (95% CI: 0.64–0.87; mPFS 18.1 vs 14.1 months), and 0.71 (95% CI: 0.59–0.85; mPFS 36.1 vs 21.4 months) for complementary standard-risk patients. The HR for PFS with ixazomib- vs placebo-based therapy was 0.68 in patients with t(4;14) (95% CI: 0.48–0.96; mPFS 22.4 vs 13.2 months), and 0.77 for patients with amp1q21 (95% CI: 0.63–0.93; mPFS 18.8 vs 14.5 months). A PFS benefit was demonstrated with ixazomib- vs placebo-based therapy regardless of cytogenetic status, with greatest benefit observed in patients with t(4;14) and amp1q21.

Details

Title
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Author
Chng, Wee-Joo 1   VIAFID ORCID Logo  ; Lonial, Sagar 2   VIAFID ORCID Logo  ; Morgan, Gareth J. 3 ; Iida, Shinsuke 4 ; Moreau, Philippe 5 ; Kumar, Shaji K. 6   VIAFID ORCID Logo  ; Twumasi-Ankrah, Philip 7 ; Villarreal, Miguel 7 ; Dash, Ajeeta B. 7   VIAFID ORCID Logo  ; Vorog, Alexander 7 ; Zhang, Xiaoquan 7 ; Suryanarayan, Kaveri 7 ; Labotka, Richard 7 ; Dimopoulos, Meletios A. 8   VIAFID ORCID Logo  ; Rajkumar, S. Vincent 6   VIAFID ORCID Logo 

1  National University Cancer Institute, Department of Hematology-Oncology, Singapore, Singapore (GRID:grid.440782.d) (ISNI:0000 0004 0507 018X); National University of Singapore, Cancer Science Institute of Singapore, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431) 
2  Emory University Medical School, Emory University, Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
3  NYU Langone Health, Perlmutter Cancer Center, New York, USA (GRID:grid.240324.3) (ISNI:0000 0001 2109 4251) 
4  Nagoya City University Institute of Medical and Pharmaceutical Sciences, Department of Hematology and Oncology, Nagoya, Japan (GRID:grid.260433.0) (ISNI:0000 0001 0728 1069) 
5  University Hospital Hotel Dieu, Hematology Department, Nantes, France (GRID:grid.277151.7) (ISNI:0000 0004 0472 0371) 
6  Mayo Clinic, Division of Hematology, Department of Internal Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
7  Takeda Development Center Americas, Inc. (TDCA), Lexington, USA (GRID:grid.419849.9) (ISNI:0000 0004 0447 7762) 
8  National and Kapodistrian University of Athens, School of Medicine, Hematology and Medical Oncology, Department of Clinical Therapeutics, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800) 
Pages
14
Publication year
2023
Publication date
Dec 2023
Publisher
Springer Nature B.V.
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41408-022-00768-5
ProQuest document ID
2764017060
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.